MedPath

RESOLUTE ONYX Post-Approval Study

Completed
Conditions
Coronary Artery Disease
Registration Number
NCT03063749
Lead Sponsor
Medtronic Vascular
Brief Summary

To observe the continued performance of the Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System in a real-world more-comer population.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
416
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Target Lesion Failure12 months

Target Lesion Failure (TLF), defined as cardiac death, target vessel myocardial infarction (Q wave and non-Q wave), or clinically driven target lesion revascularization (TLR) by percutaneous or surgical methods

Secondary Outcome Measures
NameTimeMethod
Acute Success (Device, Lesion, Procedure)30 days and 6, 12, 24, and 36 months post-procedure

Acute Success (Device, Lesion, Procedure)

Target Vessel Myocardial Infarction (TVMI)30 days and 6, 12, 24, and 36 months post-procedure

Target Vessel Myocardial Infarction (TVMI)

Target Lesion Revascularization (TLR)30 days and 6, 12, 24, and 36 months post-procedure

Target Lesion Revascularization (TLR)

Cardiac Death and TVMI30 days and 6, 12, 24, and 36 months post-procedure

Cardiac Death and TVMI

Major Adverse Cardiac Event (MACE)30 days and 6, 12, 24, and 36 months post-procedure

Defined as death, myocardial infarction (Q wave and non-Q wave), emergent coronary bypass surgery, or clinically-driven repeat target lesion revascularization by percutaneous or surgical methods

Target Vessel Revascularization (TVR)30 days and 6, 12, 24, and 36 months post-procedure

Target Vessel Revascularization (TVR)

Target Lesion Failure (TLF)30 days and 6, 12, 24, and 36 months post-procedure

Target Lesion Failure (TLF)

Cardiac Death30 days and 6, 12, 24, and 36 months post-procedure

Cardiac Death

Target Vessel Failure (TVF)30 days and 6, 12, 24, and 36 months post-procedure

Target Vessel Failure (TVF)

Stent Thrombosis (ST)30 days and 6, 12, 24, and 36 months post-procedure

Stent Thrombosis (ST)

Trial Locations

Locations (28)

Huntsville Hospital

🇺🇸

Huntsville, Alabama, United States

Scripps Green Hospital

🇺🇸

La Jolla, California, United States

Riverside Community Hospital

🇺🇸

Riverside, California, United States

Hartford Hospital

🇺🇸

Hartford, Connecticut, United States

Morton Plant Hospital

🇺🇸

Clearwater, Florida, United States

North Florida Regional Medical Center

🇺🇸

Gainesville, Florida, United States

Tallahassee Memorial Hospital

🇺🇸

Tallahassee, Florida, United States

WellStar Kennestone Hospital

🇺🇸

Marietta, Georgia, United States

University of Michigan Health System - University Hospital

🇺🇸

Ann Arbor, Michigan, United States

Mercy Hospital (Coon Rapids MN)

🇺🇸

Coon Rapids, Minnesota, United States

Scroll for more (18 remaining)
Huntsville Hospital
🇺🇸Huntsville, Alabama, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.